Jim Wassil Sells 1,381 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,381 shares of Vaxcyte stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $61.16, for a total transaction of $84,461.96. Following the completion of the sale, the executive vice president directly owned 152,228 shares in the company, valued at approximately $9,310,264.48. This represents a 0.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Wednesday, September 9th, Jim Wassil sold 1,334 shares of Vaxcyte stock. The shares were sold at an average price of $59.52, for a total transaction of $79,399.68.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total transaction of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $53.86, for a total transaction of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50.

Vaxcyte Trading Down 1.4%

Shares of NASDAQ:PCVX traded down $0.85 during mid-day trading on Wednesday, reaching $59.51. The company had a trading volume of 1,195,242 shares, compared to its average volume of 1,369,661. Vaxcyte, Inc. has a one year low of $30.81 and a one year high of $65.00. The company’s 50-day moving average price is $58.41 and its 200-day moving average price is $56.32. The firm has a market cap of $8.86 billion, a price-to-earnings ratio of -7.80 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period in the prior year, the business earned ($1.22) EPS. On average, research analysts anticipate that Vaxcyte, Inc. will post -7.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently modified their holdings of PCVX. Smartleaf Asset Management LLC boosted its position in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Vaxcyte by 1,463.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares during the period. IFP Advisors Inc lifted its stake in Vaxcyte by 72.8% in the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after purchasing an additional 236 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its holdings in Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PCVX shares. Zacks Research upgraded shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.